Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma

University of New South Wales Department of Surgery, St George Hospital, Sydney, New South Wales, Australia.
British Journal of Surgery (Impact Factor: 5.54). 01/2011; 98(1):60-4. DOI: 10.1002/bjs.7263
Source: PubMed


This study was undertaken to measure survival of patients with multicystic peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy through a multi-institutional collaboration.
A multi-institutional data registry, established by the Peritoneal Surface Oncology Group, was used to identify patients with peritoneal mesothelioma and the subgroup with multicystic tumours, treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Outcomes for this subgroup are reported. The primary endpoint was overall survival. A secondary endpoint was the incidence of treatment-related complications.
Of 405 patients with peritoneal mesothelioma, 26 (6·4 per cent) had multicystic tumours. There were 20 women and six men with a mean(s.d.) age of 42(12) years. The median peritoneal carcinomatosis index (PCI) was 14 (range 6-39). There was no perioperative mortality. Six patients developed grade III or IV complications. After a median follow-up of 54 (range 5-129) months, all 26 patients were still alive.
Multicystic peritoneal mesothelioma appears to be a distinct subtype of peritoneal mesothelioma, where long-term survival may be achieved through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

13 Reads
  • Source
    • "Sugarbaker [3], however, first described that some of these patients may benefit from the surgical removal of all macroscopic tumor, combined with locoregional chemotherapy [3]. Since then, CRS/HIPEC has increasingly been used to treat patients with peritoneal carcinomatosis of different origin [4-11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a treatment option for selected patients with peritoneal carcinomatosis. There are limited data available on anaesthesia management and its impact on patients’ outcome. Our aim was to retrospectively analyze and evaluate perioperative management and the clinical course of patients undergoing CRS/HIPEC within a three-year period. Methods After ethic committee approval, patient charts were retrospectively reviewed for patient characteristics, interventions, perioperative management, postoperative course, and complications. Analysis was intervention based. Data are presented as median (range). Results Between 2009 and 2011, 54 consecutive patients underwent 57 interventions; median anaesthesia time was 715 (range 370 to 1135) minutes. HIPEC induced hyperthermia with an overall median peak temperature of 38.1 (35.7-40.2)°C with active cooling. Bleeding, expressed as median blood loss was 0.8 (0 to 6) litre and large fluid shifts occurred, requiring a total fluid input of 8.4 (4.2 to 29.4) litres per patient. Postoperative renal function was dependent on preoperative function and the type of fluids used. Administration of hydroxyethyl starch colloid solution had a significant negative impact on renal function, especially in younger patients. Major complications occurred after 12 procedures leading to death in 2 patients. Procedure time and need for blood transfusion were associated with a significantly higher risk for major complications. Conclusions Cytoreductive surgery with HIPEC is a high-risk surgical procedure associated with major hemodynamic and metabolic changes. As well as primary disease and complexity of surgery, we have shown that anaesthesia management, the type and amount of fluids used, and blood transfusions may also have a significant effect on patients’ outcome.
    World Journal of Surgical Oncology 05/2014; 12(1):136. DOI:10.1186/1477-7819-12-136 · 1.41 Impact Factor
  • Source
    • "Complete surgical excision, is the treatment of choice, even though some centers advocate an aggressive surgical treatment including cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy. The jury is divided on the choice of treatment for recurrent disease, from selective and limited surgery for the symptoms of intestinal obstruction or other functional abnormalities and severe abdominal pain, to cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The benign cystic mesothelioma of the peritoneum is a rare lesion and is known for local recurrence. This is first case report of a rapidly developing massive abdominal tumor with histological finding of benign cystic mesothelioma (BCM). We describe a BCM arising in the retroperitoneal tissue on the right side, lifting ascending colon and cecum to the left side of abdomen. Patient was an active 58-year-old man who noticed a rapid abdominal swelling within a two month time period with a weight gain of 40 pounds. Patient had no risk factors including occupational (asbestos, cadmium), family history, social (alcohol, smoking) or history of trauma. We will discuss the clinical, radiologic, intra-operative, immunohistochemical, pathologic findings, and imaging six months after surgery. Patient has no recurrence and no weight gain on follow up visits and imaging.
    World Journal of Surgical Oncology 12/2012; 10(1):277. DOI:10.1186/1477-7819-10-277 · 1.41 Impact Factor
  • Source

    1st Macedonian Congress of Pathology with International Participation, Ohrid, Republic of Macedonia; 10/2011
Show more

Similar Publications